Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock
June 28 2021 - 4:18PM
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage
biopharmaceutical company focused on discovering and developing
small molecule therapeutics targeting fundamental biological
pathways of cancers, today announced the commencement of a proposed
underwritten public offering of $150 million of shares of its
common stock. All shares of common stock to be sold in the proposed
offering will be sold by Zentalis. Zentalis also expects to grant
the underwriters a 30-day option to purchase up to an additional
$22.5 million shares of common stock.
Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities
are acting as joint book-running managers for the offering. Wedbush
PacGrow is acting as co-manager for the offering.
The securities described above are being offered pursuant to an
effective shelf registration statement that was filed with the U.S.
Securities and Exchange Commission (SEC) on May 4, 2020. This
offering will be made only by means of a prospectus supplement and
the accompanying prospectus which forms a part of the effective
shelf registration statement.
A preliminary prospectus supplement related to the offering
(including the accompanying prospectus) will be filed with the SEC
and will be available on the SEC’s website located at www.sec.gov.
Copies of the preliminary prospectus supplement and the
accompanying prospectus may also be obtained, when available, by
contacting: Morgan Stanley & Co. LLC, Attention: Prospectus
Department, 180 Varick Street, Second Floor, New York, New York
10014, Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, New York
10022, via telephone: 877-821-7388 or via email:
Prospectus_Department@Jefferies.com, SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at (800) 808-7525, ext. 6105, or by emailing
syndicate@svbleerink.com, Guggenheim Securities, LLC Attention:
Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017
or by telephone at (212) 518-5548, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Zentalis Pharmaceuticals, Inc.Zentalis
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
focused on discovering and developing small molecule therapeutics
targeting fundamental biological pathways of cancers. The Company
is developing a broad pipeline of potentially best-in-class
oncology candidates, all internally discovered, which include
ZN-c5, an oral selective estrogen receptor degrader (SERD) for
ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor for advanced solid
tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies, and
ZN-e4, an EGFR inhibitor for non-small cell lung carcinoma (NSCLC).
Zentalis has licensed ZN-c5, ZN-c3 and ZN-d5 to its majority-owned
joint venture, Zentera Therapeutics, to develop and commercialize
these candidates in China. Zentalis has operations in both New York
and San Diego.
For more information, please visit www.zentalis.com. Follow
Zentalis on Twitter at @ZentalisP and on LinkedIn
at www.linkedin.com/company/zentalis-pharmaceuticals.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding the completion, timing, terms and size of the proposed
offering and our expectations with respect to granting the
underwriters a 30-day option to purchase additional shares. These
statements are neither promises nor guarantees, but involve known
and unknown risks, uncertainties and other important factors that
may cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to, the following: the
COVID-19 pandemic has adversely impacted and may continue to
adversely impact our business, including our preclinical studies
and clinical trials; our limited operating history, which may make
it difficult to evaluate our current business and predict our
future success and viability; we have and expect to continue to
incur significant losses; our need for additional funding, which
may not be available; our substantial dependence on the success of
our lead product candidates; failure to identify additional product
candidates and develop or commercialize marketable products; the
early stage of our development efforts; potential unforeseen events
during clinical trials could cause delays or other adverse
consequences; risks relating to the regulatory approval process or
ongoing regulatory obligations; failure to obtain U.S. or
international marketing approval; our product candidates may cause
serious adverse side effects; inability to maintain our
collaborations, or the failure of these collaborations; our
reliance on third parties; effects of significant competition; the
possibility of system failures or security breaches; risks relating
to intellectual property; our ability to attract, retain and
motivate qualified personnel; and significant costs as a result of
operating as a public company. These and other important factors
discussed under the caption “Risk Factors” in our Quarterly Report
on Form 10-Q for the quarterly period ended March 31, 2021 filed
with the SEC and our other filings with the SEC could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim
any obligation to do so, even if subsequent events cause our views
to change.Investor Contact:Gitanjali Jain
OgawaSolebury Troutgogawa@soleburytrout.com
Media Contact:Julia DeutschSolebury
Troutjdeutsch@soleburytrout.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From Apr 2023 to Apr 2024